1. Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group
- Author
-
Irvin, Marguerite R, Sitlani, Colleen M, Floyd, James S, Psaty, Bruce M, Bis, Joshua C, Wiggins, Kerri L, Whitsel, Eric A, Sturmer, Til, Stewart, James, Raffield, Laura, Sun, Fangui, Liu, Ching-Ti, Xu, Hanfei, Cupples, Adrienne L, Tanner, Rikki M, Rossing, Peter, Smith, Albert, Zilhão, Nuno R, Launer, Lenore J, Noordam, Raymond, Rotter, Jerome I, Yao, Jie, Li, Xiaohui, Guo, Xiuqing, Limdi, Nita, Sundaresan, Aishwarya, Lange, Leslie, Correa, Adolfo, Stott, David J, Ford, Ian, Jukema, J Wouter, Gudnason, Vilmundur, Mook-Kanamori, Dennis O, Trompet, Stella, Palmas, Walter, Warren, Helen R, Hellwege, Jacklyn N, Giri, Ayush, O'donnell, Christopher, Hung, Adriana M, Edwards, Todd L, Ahluwalia, Tarunveer S, Arnett, Donna K, and Avery, Christy L
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Hypertension ,Human Genome ,Cardiovascular ,Genetics ,Black or African American ,Aged ,Antihypertensive Agents ,Blood Pressure ,Case-Control Studies ,DNA (Cytosine-5-)-Methyltransferases ,DNA Methyltransferase 3A ,DNA-Binding Proteins ,Drug Resistance ,Dystrophin-Associated Proteins ,Europe ,Female ,Genetic Loci ,Genome-Wide Association Study ,Humans ,Male ,Middle Aged ,Myosin Heavy Chains ,Myosin Type V ,Neuropeptides ,Pharmacogenetics ,Pharmacogenomic Variants ,Polymorphism ,Single Nucleotide ,Risk Assessment ,Risk Factors ,Transcription Factors ,United States ,White People ,blood pressure ,hypertension ,genome-wide association study ,severe hypertension ,treatment-resistant hypertension ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundOnly a handful of genetic discovery efforts in apparent treatment-resistant hypertension (aTRH) have been described.MethodsWe conducted a case-control genome-wide association study of aTRH among persons treated for hypertension, using data from 10 cohorts of European ancestry (EA) and 5 cohorts of African ancestry (AA). Cases were treated with 3 different antihypertensive medication classes and had blood pressure (BP) above goal (systolic BP ≥ 140 mm Hg and/or diastolic BP ≥ 90 mm Hg) or 4 or more medication classes regardless of BP control (nEA = 931, nAA = 228). Both a normotensive control group and a treatment-responsive control group were considered in separate analyses. Normotensive controls were untreated (nEA = 14,210, nAA = 2,480) and had systolic BP/diastolic BP < 140/90 mm Hg. Treatment-responsive controls (nEA = 5,266, nAA = 1,817) had BP at goal (
- Published
- 2019